Expected behavior in severe preeclampsia;Conducta expectante en la preeclampsia severa

Revista de Obstetricia y Ginecologia de Venezuela

Volumn 69, Issue 1, 2009, Pages 56-62

  Perozo Romero, Juan ^a   Santos Bolívar, Joel ^a   Peña Paredes, Elvia ^a   Sabatini Sáez, Isabel ^a   Torres Cepeda, Duly ^a   Reyna Villasmil, Eduardo ^a  

^a HOSPITAL CENTRAL DR URQUINAONA   (Venezuela)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 68849119334     PISSN: 00487732     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. ACOG. Clinical Management Guidelines for Obstetrician and Gynecologists. Obstet Gynecol. 2002;99:159-167.
2. Geller S, Cox S, Callaghan W, Berg C. Morbidity and mortality in pregnancy: Laying the groundwork for safe motherhood. Womens Health Issues. 2006;16:176-188.
3. Chang J, Elam-Evans L, Berg C, Herndon J, Flowers L, Seed K, et al. Pregnancy-related mortality surveillance-United States, 1991-1999. MMWR Surveill Summ. 2003;21:1-8.
4. Berg C, Chang J, Callaghan W, Whitehead S. Pregnancy-related mortality in the United States, 1991-1997. Obstet Gynecol. 2003;101:289-296.
5. MacKay A, Berg C, Atrash H. Pregnancy-related mortality from preeelampsia and eclampsia. Obstet Gynecol. 2001;97:533-538.
6. Khan K, Wojdyla D, Say L, Gulmezoglu A, Van Look P. WHO analysis of causes of maternal death: Systematic review. Lancet. 2006;367:1066-1074.
7. Grujic I, Milasinovic L. Hypertension, pre-eclampsia and eclampsia-monitoring and outcome of pregnancy. Med Pregl. 2006;59:556-559.
8. Garner E, Goldstein D, Feltmate C, Berkowitz R. Gcstational trophoblastic disease. Clin Obstet Gynecol. 2007;50:112-122.
9. Strevens H, Wide-Swensson D, Hansen A, Horn T, Ingemarsson I, Larsen S, et al. Glomerular endotheliosis in normal pregnancy and pre-eclampsi a. BJOG. 2003;110:831-836.
10. Molina R, Romero T, Bermúdez I, Flores J, Fuenmayor J, Núñez J, et al. Factor de necrosis tumoral-alfa en el suero de embara/adas normales y preeclámpticas. Gac Méd Caracas. 2001;109:526-531.
11. Núñez J, Sanabria C, Romero T. Dctcrminación de las concentraciones séricas del factor de necrosis tumoral αy de sus receptores solubles en embarazadas normales y preeclámpticas. Invest Clín. 2001;42:171-181.
12. Visser N, van Rijn B, Rijkers G, Franx A, Bruinse H. Inflammatory changes in preeelampsia: Current understanding of the maternal innate and adaptive immune response. Obstet Gynecol Surv. 2007;62:191-201.
13. Matthiesen L, Berg G, Ernerudh J, Ekerfelt C, Jonsson Y, Sharma S. Immunology of preeelampsia. Chem Immunol Allergy. 2005;89:49-61.
14. Aure G, Lares M, Obregón O, Brito S. Evaluación de molécula-1 de adhesión vascular como indicador de activación endotelial en preeelampsia en la semana 20 de gestatió. Rev Fac Med (Caracas). 2005;28:162-168.
15. Rubio R, Hamilton A, Miranda G, Giustiniano B, González R, García G. Lipoproteínas e hipertensión inducida por el embarazo. Gac Méd Caracas. 2003;111:206-210.
16. Contreras F, Martinez J, Fouillioux C, Colmenares Y, Guevarra K, Torres D, et al. Hndotelio y trastornos hipertensivos en el embarazo. Rev Fac Med (Caracas). 2002;25:121-129.
17. Núñez J, Sanabria C, Romero T, Núñez L, Montiel I, Boscán F, et al. Óxido nítrico, malondialdehído, perfil lipídico, factor de necrosis tumoral alfa y sus receptores solubles en mujeres no embarazadas, gestantes normales y preeclámpticas. Gac Méd Caracas. 2001;109:352-360.
18. Reyna E, Prieto M, Torres M, Reyna N, Mejía J. Alteratión en el metabolisme de los carbohidratos y lípidos en mujeres que han sufrido preeelampsia. Rev Obstet Ginecol Venez. 2002;62:97-102.
19. Reyna E, Prieto M, Torres M, Reyna N, Mejía J. Peroxidación lipídica en embarazos con preeelampsia y diabetes. Rev Obstet Ginecol Venez. 2002;62:93-96.
20. Reyna E, Prieto M, Torres M, Reyna N, Mejía J. Metabolites del óxido nítrico plasmático y niveles de peróxidos lipídicos en pacientes preeclámpticas antes y después del parto. Rev Obstet Ginecol Venez. 2002;62:89-92.
21. Molina R, Romero 'T, Ruiz A. Citocinas en la fisiopatología de la preeelampsia. Gac Méd Caracas. 1999;107:505-516.
22. Guzin K, Tomruk S, Tuncay Y, Naki M, Sezginsoy S, Zemhcri E, et al. 'The relation of increased uterine artery blood flow resistance and impaired trophoblast invasioninpre-eclamptic pregnancies. Arch Gynecol Obstet. 2005;272:283-288.
23. Ayuk P, Matijevic R. Placental ischaemia is a consequence rather than a cause of pre-eclampsia. Med Hypotheses. 2006;67:792-795.
24. Kimber S. Molecular interactions at the maternal-embryonic interface during the early phase of implantation. Semin Reprod Med. 2000;18:237-253.
25. Staff A, Braekke K, Harsem N, Lyberg T, Holthe M. Circulating concentrations of sFltl (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia. Eur J Obstet Gynecol Reprod Biol. 2005;122:33-39.
26. Thadhani R, Mutter W, Wolf M, Levine R, Taylor R, Sukhatme V, et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab. 2004;89:770-775.
27. Sibai B. Caring for women with hypertension in pregnancy. JAMA. 2007;298:1566-1568.
28. Heydanus R, Defoort P, Dhont M. Pre-eclampsia and trisomy 13. Hur I Obstet Gynecol Reprod Biol. 1995;60:201-202.
29. Norwitz E, Robinson J, Repke J. Prevention of preeclampsia: Is it possible? Clin Obstet Gynecol. 1999;42:436-454.
30. Smith R, Baker P. Risk factors, prevention and treatment of hypertension in pregnancy. Minerva Ginecol. 2005;57:379-388.
31. Moore L, Rayburn W. Elective induction of labor. Clin Obstet Gynecol. 2006;49:698-704.
32. Chibber R. Severe preeclampsia and the very-lowbirth-weight infant. The controversy over delivery mode continues. J Reprod Med. 2002;47:925-930.
33. Sibai B, Barton J. Expectant management of severe preeclampsia remote from term: Patient selection, treatment, and delivery indications. Am J Obstet Gynecol. 2007;196:514-519.
34. Louis J, Ehrenberg H, Collin M, Mercer B. Perinatal intervention and neonatal outcomes near the limit of viability. Am J Obstet Gynecol. 2004;191:1398-1402.
35. Buchbinder A, Sibai B, Caritis S, Macpherson C, Hauth J, Lindheimer M, et al. Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia. Am J Obstet Gynecol. 2002;186:66-71.
36. Perlman J, Risser R, Gee J. Pregnancy-induced hypertension and reduced intraventricular hemorrhage in preterai infants. Pediatr Neurol. 1997; 17:29-33.
37. NIH Consensus Development Panel. Antenatal corticosteroids revisited: Repeat courses - National Institutes of Health Consensus Development Conference Statement, August 17-18, 2000. Obstet Gynecol. 2001;98:144-150.
38. Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterai birth. Cochrane Database Syst Rev. 2006;19:CD004454.
39. Vermillion S, Bland M, Soper D. Effectiveness of a rescue dose of antenatal betamethazone after an initial course. Am J Obstet Gynecol. 2001;185:1086-1089.
40. Hall D, Odendaal H, Steyn D. Expectant management of severe pre-eclampsia in the mid-trimester. Eur J Obstet Gynecol Reprod Biol. 2001;96:168-172.
41. Sibai B, Spinnato J, Watson D, Hill G, Anderson G. Pregnancy outcome in 303 cases with severe preeclampsia. Obstet Gynecol. 1984;64:319-325.
42. Romero J, Lara A, Izquierdo C. Conservative management in severe pre-eclampsia. Ginecol Obstet Méx. 2000;68:51-54.
43. Brieeño C, Briceño L. Evidence-based obstetric conduct. Severe preeclampsia: Aggressive or expectant management? Ginecol Obstet Méx. 2006;75:95-103.
44. Schiff E, Friedman S, Kao L, Sibai B. The importance of urinary protein excretion during conservative management of severe preeclampsia. Am J Obstet Gynecol. 1996;175:1313-1316.
45. Hall D, Odendaal H, Steyn D, Grive D. Urinary protein excretion and expectant management of early onset, severe preeclampsia. Int J Gynaecol Obstet. 2002;77:1-6.
46. Baumwell S, Karumanchi S. Pre-eclampsia: Clinical manifestations and molecular mechanisms. Nephron Clin Pract. 2007;106:72-81.
47. Shear R, Rinfret D, Leduc L. Should we offer expectant management in cases of severe preterm preeclampsia with fetal growth restriction? Am J Obstct Gynecol. 2005; 192:1119-1125.
48. Ebrashy A, Azmy O, Ibrahim M, Waly M, Edris A. Middle cerebral/umbilical artery resistance index ratio as sensitive parameter for fetal well-being and neonatal outcome in patients with preeclampsia: Case-control study. Croat Med J. 2005;46:821-825.
49. Haddad B, Deis S, Goffinet F, Paniel B, Cabrol D, Sibai B. Maternal and perinatal outcomes during expectant management of 239 severe preeclamptic women between 24 and 33 weeks' gestation. Am J Obstet Gynecol. 2004;190:1590-1595.
50. Sibai B, Mercer B, Schiff E, Friedman S. Aggressive versus expectant management of severe preeclampsia at 28 to 32 weeks' gestation: A randomized controlled trial. Am J Obstet Gynecol. 1994;171:818-822.
51. Friedman S, Schiff E, Lubarsky S, Sibai B. Expectant management of severe preeclampsia remote from term. Clin Obstet Gynecol. 1999;42:470-478.
52. Magee L, von Dadelszen P, Chan S, Gafni A, Gruslin A, Helewa M, et al. The Control of Hypertension In Pregnancy Study pilot trial. BJOG. 2007;114:e13-20.
53. Sibai B, Barton J, Akl S, Sarinoglu C, Mercer B. A randomized prospective comparison of nifedipine and bed rest versus bed rest alone in the management of preeclampsia remote from term. Am J Obstet Gynecol. 1992;167:879-884.
54. Ferrer R, Sibai B, Mulrow C, Chiquette E, Stevens K, Cornell J. Management of mild chronic hypertension during pregnancy: A review. Obstet Gynecol. 2000;96:849-860.
55. Caniggia I, Winter J, Lye S, Post M. Oxygen and placental development during the first trimester: Implications for the pathophysiology of pre-cclampsia. Placenta. 2000;21(Suppl):25-30.
56. Borghi C, Dormi A, L'Italien G, Lapuerta P, Franklin S, Collatina S, et al. The relationship between systolic blood pressure and cardiovascular risk-results of the Brisighella Heart Study. J Clin Hypertens. 2003;5:47-52.
57. Pritchard J, Weisman R, Ratnoff O, Vosburgh G. Intravascular hcmolysis, thrombocytopenia and other hematologie abnormalities associated with severe toxemia of pregnancy. N Engl J Med. 1954;21:89-98.
58. Weinstein L. Syndrome of hemolysis, elevated liver enzymes, and low platelet count: Asevere consequence of hypertension in pregnancy. Am J Obstet Gynecol. 1982; 142:159-167.
59. Fisher S. The placental problem: Linking abnormal cytotrophoblast differentiation to the maternal symptoms of preeclampsia. Reprod Biol Endocrinol. 2004;2:53.
60. Ganzevoort W, Rep A, Bonsel G, Fetter W, van Sonderen L, De Vries J, et al. Arandomisedcontrolled trial comparing two temporising management strategies, one with and one without plasma volume expansion, for severe and early onset pre-eclampsia. BJOG. 2005; 112:1358-1368.
61. Sibai B. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol. 2004;103:981-991.
62. Roelofsen A, van Pampus M, Aamoudse J. The HELLP-syndrome; maternal-fetal outcome and follow up of infants. J Perinat Med. 2003;31:201-208.
63. Crane J, Tabarsi B, Hutchens D. The maternal benefits of corticosteroids with HELLP (hemolysis, elevated liver enzymes, low platelet count) syndrome. J Obstet Gynaecol Can. 2003;25:650-655.
64. Isler C, Magann E, Rinehart B, Terrone D, Bass J, Martin J. Dexamethasone compared with betamethasone for glucocorticoid treatment of postpartumHELLP syndrome. Int J Gynaecol Obstet. 2003;80:291-297.